We are live on ! Find out more
IONS icon

Ionis Pharmaceuticals
IONS

369 hedge funds and large institutions have $7.3B invested in Ionis Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 42 funds opening new positions, 124 increasing their positions, 119 reducing their positions, and 69 closing their positions.

New
Increased
Maintained
Reduced
Closed

4% more repeat investments, than reductions

Existing positions increased: 124 | Existing positions reduced: 119

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

3% less call options, than puts

Call options by funds: $94.6M | Put options by funds: $97.4M

3.45% less ownership

Funds ownership: 90.24% → 86.79% (-3.4%)

7% less funds holding

Funds holding: 396 → 369 (-27)

10% less capital invested

Capital invested by funds: $8.14B → $7.3B (-$833M)

39% less first-time investments, than exits

New positions opened: 42 | Existing positions closed: 69

Holders
369
Holders Change
-27
Holders Change %
-6.82%
% of All Funds
8.09%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.13%
New
42
Increased
124
Reduced
119
Closed
69
Calls
$94.6M
Puts
$97.4M
Net Calls
-$2.81M
Net Calls Change
+$35.2M

Top Buyers

1
BI
BVF Inc
California
+$61M
2
APG Asset Management
APG Asset Management
Netherlands
+$31M
3
BG
Bellevue Group
Switzerland
+$23.8M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$17.9M
5
GPP
Great Point Partners
Connecticut
+$17.6M

Top Sellers

1
Goldman Sachs
Goldman Sachs
New York
-$59.9M
2
Deutsche Bank
Deutsche Bank
Germany
-$47.9M
3
First Trust Advisors
First Trust Advisors
Illinois
-$45.6M
4
Two Sigma Investments
Two Sigma Investments
New York
-$42.6M
5
Vanguard Group
Vanguard Group
Pennsylvania
-$41.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
DY
26
Dowling & Yahnke
California
$40.5M – – –
Two Sigma Investments
27
Two Sigma Investments
New York
$39.6M -$42.6M -654,074 -50%
APG Asset Management
28
APG Asset Management
Netherlands
$36.8M +$31M +476,087 +246%
Charles Schwab
29
Charles Schwab
California
$35.2M -$1.85M -28,414 -5%
Janus Henderson Group
30
Janus Henderson Group
United Kingdom
$34.9M +$17.9M +274,852 +89%
Goldman Sachs
31
Goldman Sachs
New York
$34.2M -$59.9M -918,846 -62%
Bank of New York Mellon
32
Bank of New York Mellon
New York
$32.8M +$117K +1,800 +0.3%
N
33
Nuveen
North Carolina
$29.9M +$1.06M +16,278 +3%
Mitsubishi UFJ Trust & Banking
34
Mitsubishi UFJ Trust & Banking
Japan
$28.5M -$1.93M -29,577 -6%
Swiss National Bank
35
Swiss National Bank
Switzerland
$26.4M +$747K +11,459 +3%
SA
36
Sicart Associates
New York
$24.6M -$185K -2,835 -0.7%
TAM
37
Tocqueville Asset Management
New York
$24.5M -$2.41M -37,008 -8%
Stifel Financial
38
Stifel Financial
Missouri
$24.4M -$1.14M -17,422 -4%
Legal & General Group
39
Legal & General Group
United Kingdom
$23.4M +$2.25M +34,465 +10%
NAMA
40
Nikko Asset Management Americas
New York
$21.8M +$3.66M +56,089 +18%
UBS AM
41
UBS AM
Illinois
$20.2M +$78.7K +1,207 +0.4%
FLAM
42
First Light Asset Management
Minnesota
$19.4M -$162K -2,483 -0.8%
CS
43
Candriam SCA
Luxembourg
$17.6M – – –
California Public Employees Retirement System
44
California Public Employees Retirement System
California
$17.5M +$4.82M +74,015 +34%
AGA
45
Altrinsic Global Advisors
Connecticut
$17.3M +$7.19M +110,384 +62%
Dimensional Fund Advisors
46
Dimensional Fund Advisors
Texas
$16.8M +$485K +7,434 +3%
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
$16.3M -$1.75M -26,843 -9%
GPP
48
Great Point Partners
Connecticut
$16.2M +$17.6M +270,000 New
Axa
49
Axa
France
$15.8M -$1.2M -18,456 -7%
Franklin Resources
50
Franklin Resources
California
$15.8M – – –
1
2
3 4 5

IONS Hedge Fund Activity: Q3 2019 in Review

369 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Ionis Pharmaceuticals (IONS) for Q3 2019, worth a combined $7.3B — down 10% from $8.14B a quarter earlier.

Sellers outnumbered buyers: 69 funds closed out of IONS and 42 opened new positions — a net loss of 27 holders — while 119 trimmed existing stakes and 124 added.

The largest buyer was BVF Inc, opening a new position worth an estimated $61M. The largest seller was Goldman Sachs, cutting an estimated $59.9M.

  • 369 institutional investors held Ionis Pharmaceuticals (IONS) as of Q3 2019, down from 396 in Q2 2019.
  • Funds reported $7.3B of Ionis Pharmaceuticals stock for Q3 2019, down 10% quarter-over-quarter.
  • 42 funds opened new Ionis Pharmaceuticals positions in Q3 2019 and 69 closed out, a net change of -27 holders.
  • The largest Ionis Pharmaceuticals buyer in Q3 2019 was BVF Inc, an estimated $61M added.
  • The largest Ionis Pharmaceuticals seller in Q3 2019 was Goldman Sachs, an estimated $59.9M sold.

Based on aggregated 13F filings for Q3 2019.